Literature DB >> 31933170

Cenobamate: First Approval.

Susan J Keam1.   

Abstract

Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients. This article summarizes the milestones in the development of cenobamate leading to this first approval.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31933170     DOI： 10.1007/s40265-019-01250-6

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  3 in total

1.  Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.

Authors:  Gregory L Krauss; Pavel Klein; Christian Brandt; Sang Kun Lee; Ivan Milanov; Maja Milovanovic; Bernhard J Steinhoff; Marc Kamin
Journal:  Lancet Neurol       Date:  2019-11-14       Impact factor: 44.182

2.  Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons.

Authors:  Michiko Nakamura; Jin-Hwa Cho; Hyewon Shin; Il-Sung Jang
Journal:  Eur J Pharmacol       Date:  2019-05-04       Impact factor: 4.432

3.  Suppression of the photoparoxysmal response in photosensitive epilepsy with cenobamate (YKP3089).

Authors:  Dorothee G A Kasteleijn-Nolst Trenite; Bree D DiVentura; John R Pollard; Gregory L Krauss; Sarah Mizne; Jacqueline A French
Journal:  Neurology       Date:  2019-07-10       Impact factor: 9.910
  3 in total
  4 in total

Review 1.  [Cenobamate-a new perspective for epilepsy treatment].

Authors:  Bernhard J Steinhoff
Journal:  Nervenarzt       Date:  2020-09-29       Impact factor: 1.214

Review 2.  Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug.

Authors:  Michał Wiciński; Oskar Puk; Bartosz Malinowski
Journal:  Neurochem Res       Date:  2020-11-30       Impact factor: 3.996

Review 3.  Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents.

Authors:  Ana Matošević; Anita Bosak
Journal:  Arh Hig Rada Toksikol       Date:  2020-12-31       Impact factor: 2.078

4.  Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study.

Authors:  Jacqueline A French; Steve S Chung; Gregory L Krauss; Sang Kun Lee; Maciej Maciejowski; William E Rosenfeld; Michael R Sperling; Marc Kamin
Journal:  Epilepsia       Date:  2021-07-13       Impact factor: 5.864
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.